Evaluation of the effect of Pycnogenol® and Tranexamic Acid in the treatment of facial stains

Not Applicable

Recruiting

• Conditions: Skin disorders; C16.131.831

• Registration Number: RBR-4jrbdk
• Lead Sponsor: Faculdade de Medicina de Botucatu (FMB Unesp)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-12-05
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: Female
• Target Recruitment: Not specified

Inclusion Criteria

Women between the ages of 18 and 60 with facial melasma; without treatment for at least 60 days; except for the use of sunscreen.

Exclusion Criteria

Patients with concomitant facial dermatoses; photosensitivity dermatoses; collagenosis; blood dyscrasias and / or under the use of anticoagulant medication; history of thrombosis; immunosuppressed patients will be excluded; pregnant; lactating women. Phenotypic extremes will be excluded: red and black because melasma is rarely mentioned in these groups. Obese; smokers; personal history of abortion; sedentary; with personal or family history of previous thrombotic event (pulmonary thromboembolism or deep vein thrombosis) are at greater risk of thromboembolism and, therefore, contraindication to the use of oral tranexamic acid.

Study & Design

• Study Type: Intervention
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Reduction of facial melasma pigmentation, verified by variation of the mMASI ocorre of at least 20%, in the before and after interventor measurements.

Secondary Outcome Measures

Name	Time	Method
Reduction of melasma pigmentation, verified by colorimetric index variation and MELASQoL by at least 20% in the before and after interventor measurements.